350,220 Boston Scientific Corporation $BSX Shares Sold by Sumitomo Mitsui Financial Group Inc.

Sumitomo Mitsui Financial Group Inc. trimmed its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 42.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 474,844 shares of the medical equipment provider’s stock after selling 350,220 shares during the period. Sumitomo Mitsui Financial Group Inc.’s holdings in Boston Scientific were worth $20,727,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Boston Scientific during the second quarter worth $5,534,781,000. Primecap Management Co. CA purchased a new position in shares of Boston Scientific in the second quarter valued at $2,156,233,000. Jupiter Topco LLC purchased a new position in shares of Boston Scientific in the second quarter valued at $803,357,000. Bank of America Corp DE purchased a new position in shares of Boston Scientific in the second quarter valued at $556,026,000. Finally, Legal & General Group Plc bought a new stake in shares of Boston Scientific during the 2nd quarter valued at $431,890,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BSX. Wells Fargo & Company dropped their price objective on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a report on Thursday, October 29th. TD Cowen downgraded Boston Scientific from a “buy” rating to a “hold” rating and cut their target price for the stock from $56.00 to $46.00 in a research note on Friday, October 30th. Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 target price (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Leerink Partners decreased their price target on Boston Scientific from $55.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, October 29th. Finally, Royal Bank Of Canada decreased their price target on Boston Scientific from $70.00 to $52.00 and set an “outperform” rating on the stock in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $61.43.

Get Our Latest Stock Analysis on BSX

Boston Scientific Stock Down 2.4%

BSX opened at $41.96 on Friday. The company has a fifty day moving average price of $43.83 and a 200-day moving average price of $53.26. The firm has a market capitalization of $60.82 billion, a P/E ratio of 17.78, a price-to-earnings-growth ratio of 1.29 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81. Boston Scientific Corporation has a one year low of $39.57 and a one year high of $101.91.

Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The business’s quarterly revenue was up 1.4% on a year-over-year basis. Equities research analysts expect that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Boston Scientific Profile

(Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

See Also

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.